Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04005378 · ClinicalTrials.gov registry record · Phase 4
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
A Phase 4 study of First Episode Psychosis, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT04005378: Recruiting Phase 4 study of First Episode Psychosis, sponsored by Northwell Health.
NCT04005378 is a Phase 4 study of First Episode Psychosis that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 300 participants, below the 6,395-participant average among 8 other First Episode Psychosis trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04005378, a Phase 4 study of First Episode Psychosis, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participants still receiving care but at high risk for disengagement and to intervene to prevent/delay disengagement.
Primary Outcome
Rate of disengagement from CSC program
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER CSC Step-down intervention
Study Locations (3)
Michigan
- InterAct of Michigan - Grand Rapids
- InterAct of Michigan - Kalamazoo
Florida
- Henderson Behavioral Health - Lauderdale Lakes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 4 |
What NCT04005378 shows while recruiting
NCT04005378 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 6,395-participant average among 8 other First Episode Psychosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with First Episode Psychosis appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT04005378 reports a single indexed study location in Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT04005378 about?
NCT04005378 is a clinical study titled "Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs". Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participants still receiving care but at high risk for disengagement and to intervene to prevent/delay disengag...
What is the current status of trial NCT04005378?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2020-07-01. Estimated completion is 2024-11-30.
What conditions does trial NCT04005378 study?
This clinical trial studies the following conditions: First Episode Psychosis.
What interventions are being tested in trial NCT04005378?
The interventions under investigation include: Usual Care (OTHER), CSC Step-down intervention (OTHER).
Who is sponsoring clinical trial NCT04005378?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04005378 being conducted?
This trial has 3 study locations across Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for First Episode Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04005378's enrollment target sits among peer trials
300 4th of 8 higher than 5 of 8 other First Episode Psychosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other First Episode Psychosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Artificial Intelligence to Measure Adherence to Oral Medication
RECRUITING · Phase 4
-
Pilot RCT of Self-stigma Treatment for First Episode Psychosis
RECRUITING · NA
-
Digital Strategies to Advance Help-Seeking Aim 1 and 2
RECRUITING
-
Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes
RECRUITING
-
Digital Strategies to Advance Help-Seeking - Aim 3
RECRUITING · NA
-
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI